Opinion|Videos|October 29, 2024
DYNAMIC: ctDNA-Guided Therapy on Adjuvant Chemotherapy Decisions in Stage II Colon Cancer
Panelists discuss how the DYNAMIC trial data demonstrate the potential of circulating tumor DNA (ctDNA)–guided therapy to inform and optimize adjuvant chemotherapy decisions in patients with stage II colon cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
Building out a Radiopharmaceuticals Program in Oncology Care
3
Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma
4
How Emory Became the First Adopter of the Liberty Endovascular Robotic System
5